Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Subcutaneous Immunoglobulin (IgSC) Gammanorm® on the Distribution of IgG Subclasses and on the Humoral Immunity of Patients With Secondary Immunodeficiency.

NCT03369301 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT03369301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03369301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Subcutaneous Immunoglobulin (IgSC) Gammanorm® on the Distribution of IgG Subclasses and on the Humoral Immunity of Patients With Secondary Immunodeficiency.
Lead sponsor
Octapharma
Phase
Observational
Overall status
Completed
Start date
September 25, 2017
Completion date
November 22, 2019
Enrollment
102 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

secondary immune deficiency